ArticleScience translational medicine2015
A synthetic fibrin cross-linking polymer for modulating clot properties and inducing hemostasis.
Article in Science translational medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
75 citing papers in PubMed, 177 citations in OpenAlex.
- Shelf-Stable, Rapid-Gelling, and Robust Thrombin-Independent Fibrinogen-Based Hydrogels for Massive Hemorrhage Control.Advanced healthcare materials · 2026Article
- Platelet Products and Artificial Platelets for Regenerative Medicine.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2026Review
- Natural Polymer-Based Hemostatic Hydrogels with Advanced Material and Structural Designs for Functional Applications.Pharmaceutics · 2026Review
- Dual-Network Protein Hydrogels Promote Rapid Hemostasis and Immune-Regulated Scarless Tissue Regeneration.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- A Single-Component Adhesive Sponge Based on Blood-Triggered and Autopenetrative Adhesion for Robust Vascular Closure.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Biosynthetic blood surrogates: Current status and future opportunities.Bioengineering & translational medicine · 2025Review
- Investigating PolySTAT's role in clot contraction and fibrin network mechanics.Biomaterials science · 2025Article
- Immunomodulatory Delivery Materials for Tissue Repair.Advanced healthcare materials · 2025Review
- Delivery of a fibrin-binding hemostatic polymer ameliorates neurovascular damage and neural tissue loss after traumatic brain injury.Science advances · 2025Article
- Covalently reactive microparticles imbibe blood to form fortified clots for rapid hemostasis and prevention of rebleeding.Nature communications · 2025Article
- Bioactive hemostatic materials: a new strategy for promoting wound healing and tissue regeneration.MedComm · 2025Review
- Transfusion biomaterials for hemostasis.Journal of thrombosis and haemostasis : JTH · 2025Review
- Injectable platelet-mimicking silk protein-peptide conjugate microspheres for hemostasis modulation and targeted treatment of internal bleeding.Journal of nanobiotechnology · 2025Article
- Spatial Control of CAR T Cell Activation Using Tumor-Homing Polymers.Journal of the American Chemical Society · 2025Article
- Reprograming Clots for In Vivo Chemical Targeting in Traumatic Brain Injury.Advanced materials (Deerfield Beach, Fla.) · 2024Article
- Injectable and rapidly expandable thrombin-decorated cryogels achieve rapid hemostasis and high survival rates in a swine model of lethal junctional hemorrhage.Bioactive materials · 2024Article
- Hydrophobic Polystyrene-Modified Gelatin Enhances Fast Hemostasis and Tissue Regeneration in Traumatic Brain Injury.Advanced healthcare materials · 2023Article
- ENGINEERED INTRAVENOUS THERAPIES FOR TRAUMA.Current opinion in biomedical engineering · 2023Article
- Advances in haemostatic sponges: Characteristics and the underlying mechanisms for rapid haemostasis.Bioactive materials · 2023Review
- Engineering a Two-Component Hemostat for the Treatment of Internal Bleeding through Wound-Targeted Crosslinking.Advanced healthcare materials · 2023Article
15 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Clotting factor replacement is the standard management of acute bleeding in congenital and acquired bleeding disorders. We present a synthetic approach to hemostasis using an engineered hemostatic polymer (PolySTAT) that circulates innocuously in the blood, identifies sites of vascular injury, and promotes clot formation to stop bleeding. PolySTAT induces hemostasis by cross-linking the fibrin matrix within clots, mimicking the function of the transglutaminase factor XIII. Furthermore, synthetic PolySTAT binds specifically to fibrin monomers and is uniformly integrated into fibrin fibers during fibrin polymerization, resulting in a fortified, hybrid polymer network with enhanced resistance to enzymatic degradation. In vivo hemostatic activity was confirmed in a rat model of trauma and fluid resuscitation in which intravenous administration of PolySTAT improved survival by reducing blood loss and resuscitation fluid requirements. PolySTAT-induced fibrin cross-linking is a novel approach to hemostasis using synthetic polymers for noninvasive modulation of clot architecture with potentially wide-ranging therapeutic applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.